BIO-TECHNE DECLARES DIVIDEND
Bio-Techne (NASDAQ: TECH) has declared a quarterly dividend of $0.08 per share for the quarter ended September 30, 2024. The dividend will be paid on November 22, 2024, to shareholders of record as of November 11, 2024. The company, which provides innovative tools and bioactive reagents for research and clinical diagnostics, reported net sales of approximately $1.2 billion in fiscal 2024 and employs around 3,100 people globally.
Bio-Techne (NASDAQ: TECH) ha dichiarato un dividendo trimestrale di $0.08 per azione per il trimestre terminato il 30 settembre 2024. Il dividendo sarà corrisposto il 22 novembre 2024 agli azionisti registrati al 11 novembre 2024. L'azienda, che fornisce strumenti innovativi e reagenti bioattivi per la ricerca e la diagnostica clinica, ha riportato vendite nette di circa $1.2 miliardi nell'anno fiscale 2024 e impiega circa 3.100 persone a livello globale.
Bio-Techne (NASDAQ: TECH) ha declarado un dividendo trimestral de $0.08 por acción para el trimestre que terminó el 30 de septiembre de 2024. El dividendo se pagará el 22 de noviembre de 2024 a los accionistas registrados a fecha del 11 de noviembre de 2024. La compañía, que proporciona herramientas innovadoras y reactivos bioactivos para la investigación y el diagnóstico clínico, reportó ventas netas de aproximadamente $1.2 mil millones en el año fiscal 2024 y emplea alrededor de 3,100 personas en todo el mundo.
Bio-Techne (NASDAQ: TECH)는 2024년 9월 30일로 종료된 분기 동안 주당 $0.08의 분기 배당금을 선언했습니다. 배당금은 2024년 11월 22일에 2024년 11월 11일 기준 주주에게 지급됩니다. 혁신적인 도구와 생리활성이 있는 시약을 연구 및 임상 진단을 위해 제공하는 이 회사는 2024 회계연도에 약 $1.2십억의 순매출을 기록하였으며, 전 세계적으로 약 3,100명의 직원을 고용하고 있습니다.
Bio-Techne (NASDAQ: TECH) a annoncé un dividende trimestriel de $0.08 par action pour le trimestre terminé le 30 septembre 2024. Le dividende sera payé le 22 novembre 2024 aux actionnaires enregistrés au 11 novembre 2024. L'entreprise, qui fournit des outils innovants et des réactifs bioactifs pour la recherche et le diagnostic clinique, a rapporté des ventes nettes d'environ $1.2 milliard pour l'exercice 2024 et emploie environ 3 100 personnes dans le monde.
Bio-Techne (NASDAQ: TECH) hat eine vierteljährliche Dividende von $0.08 pro Aktie für das am 30. September 2024 endende Quartal erklärt. Die Dividende wird am 22. November 2024 an die Aktionäre ausgezahlt, die am 11. November 2024 registriert sind. Das Unternehmen, das innovative Werkzeuge und bioaktive Reagenzien für Forschung und klinische Diagnostik bereitstellt, berichtete von Nettoverkäufen von etwa $1.2 Milliarden im Geschäftsjahr 2024 und beschäftigt weltweit rund 3.100 Mitarbeiter.
- Generated $1.2 billion in net sales for fiscal 2024
- Maintains consistent dividend payment policy
- Strong market presence with thousands of products in portfolio
- None.
Bio-Techne Corporation (NASDAQ: TECH) is a global life sciences company providing innovative tools and bioactive reagents for the research and clinical diagnostic communities. Bio-Techne products assist scientific investigations into biological processes and the nature and progress of specific diseases. They aid in drug discovery efforts and provide the means for accurate clinical tests and diagnoses. With thousands of products in its portfolio, Bio-Techne generated approximately
Forward Looking Statements:
Our press releases may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act. Such statements involve risks and uncertainties that may affect the actual results of operations. Forward looking statements in this press release include statements regarding potential future repurchase of Bio-Techne common stock. The following important factors, among others, have affected and, in the future, could affect the Company's actual results and future share price: the effect of new branding and marketing initiatives, the integration of new businesses and leadership, the introduction and acceptance of new products, the funding and focus of the types of research by the Company's customers, the impact of the growing number of producers of biotechnology research products and related price competition, general economic conditions, the impact of currency exchange rate fluctuations, and the costs and results of research and product development efforts of the Company and of companies in which the Company has invested or with which it has formed strategic relationships.
For additional information concerning such factors, see the section titled "Risk Factors" in the Company's annual report on Form 10-K and quarterly reports on Form 10-Q as filed with the Securities and Exchange Commission. We undertake no obligation to update or revise any forward-looking statements we make in our press releases due to new information or future events. Investors are cautioned not to place undue emphasis on these statements.
Contact: | David Clair, Vice President, Investor Relations & Corporate Development |
612-656-4416 |
View original content to download multimedia:https://www.prnewswire.com/news-releases/bio-techne-declares-dividend-302290718.html
SOURCE Bio-Techne Corporation
FAQ
When will Bio-Techne (TECH) pay its latest quarterly dividend?
What is Bio-Techne's (TECH) dividend amount for Q3 2024?
What was Bio-Techne's (TECH) net sales in fiscal 2024?
What is the record date for Bio-Techne's (TECH) latest dividend?
